Diabetes Increase the Mortality of Patients with COVID-19: A Meta-Analysis
Posted: 16 Apr 2020
Date Written: April 15, 2020
Abstract
Aims: Nowadays, the ongoing pandemic of COVID-19 caused by the novel coronavirus Syndrome-Coronavirus-2 (SARS-CoV-2) is an emerging, rapidly evolving situation. Complications such as hypertension, diabetes, COPD, cardiovascular disease, and cerebrovascular disease are major risk factors for patients with COVID-19.
Method: No meta-analysis has explored if or not diabetes related to mortality of patients with COVID-19. Therefore, this meta-analysis first aims to explored the possible clinical mortality between diabetes and COVID-19, and analysis if diabetes patients infected with SARS-CoV-2 are particularly likely to have the worst clinical prognostic risk and to evaluate the strength of the evidence.
Results: Our results found a significant relationship between diabetes and mortality COVID-19, with a pooled OR of 1.70 (95% CI: 1.16-2.48; P=0.006). The pooled data was calculated with the fixed effects model (FEM) as a low heterogeneity within the studies. Sensitivity analysis showed that after omitting any single study or converting a random effect model (REM) to FEM, the main results still held.
Conclusions: Our meta-analysis showed that diabetes increases the mortality of patients with COVID-19. More importantly, this meta-analysis grades the strength of evidence for further basic and clinical research into the diabetes dysfunction in COVID-19 patients.
Note: Funding: This work is not supported by grants.
Conflict of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Keywords: COVID-1, SARS-CoV-2, Diabetes, Meta-analysis
Suggested Citation: Suggested Citation